Domov › Adenokarcinom požiralnika › Tennessee
Klinične študije za Adenokarcinom požiralnika v Tennessee
13 študij za Adenokarcinom požiralnika išče udeležence na lokacijah v Tennessee.
Mesta v Tennessee
Uradno besedilo študije (angleško)
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
- Tennessee Oncology, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07544589Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- University of Tennessee - Knoxville, Knoxville
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06203600A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07090499A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Baptist Cancer Center - Memphis, Memphis
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Pllc, Nashville
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06324357A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07277413Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Nashville
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07431281A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT07182149A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Erlanger Health, Inc, Chattanooga
- The West Clinic, Germantown
- SCRI Oncology Partners, Nashville
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT06330064A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- SCRI Oncology Partners, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 15. jul. 2026 · NCT06657144A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- US Oncology Research LLC, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT04389632Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- Gastrointestinal Associates, PC, Knoxville
Vključevanje udeležencev
Starost 18–89 · Vsi spoli · Posodobljeno 1. jul. 2026 · NCT05530343A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- Sarah Cannon Research Institute, Nashville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 8. maj 2026 · NCT05954312Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.